StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Gain Therapeutics's operating margin for the twelve months ending Dec 31, 2023 was -40328.3%. For fiscal 2023 it was -40328.3%, against -12688.1% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-40328.3%−27640.2
FY2022Dec 31, 2022-12688.1%−4308.3
FY2021Dec 31, 2021-8379.8%+3667.7
FY2020Dec 31, 2020-12047.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2023Mar 31, 2023-9477.7%+7475.8
Q2 FY2022Jun 30, 2022-5443.0%−1501.7
Q1 FY2022Mar 31, 2022-7306.8%+39512.7
Q4 FY2021Dec 31, 2021-7426.3%+10252.1
Q3 FY2021Sep 30, 2021-16953.5%−4721.0
Q2 FY2021Jun 30, 2021-3941.3%+4413.7
Q1 FY2021Mar 31, 2021-46819.4%−39142.8
Q4 FY2020Dec 31, 2020-17678.5%–
Q3 FY2020Sep 30, 2020-12232.5%–
Q2 FY2020Jun 30, 2020-8355.0%–
Q1 FY2020Mar 31, 2020-7676.6%–

More Gain Therapeutics figures

See a number that looks wrong?